Donor challenge: Your generous donation will be matched 2-to-1 right now. Dear Internet Archive Supporter,. I ask only once a year. Sakramenty Dekalog Ojcze nasz. New York, New York: Also removed when Guevara was captured were his 30,word, hand-written diary, kkj collection of his personal poetry, and a short story he had authored about a young Communist guerrilla who learns to overcome his fears.
|Published (Last):||24 August 2013|
|PDF File Size:||4.60 Mb|
|ePub File Size:||6.76 Mb|
|Price:||Free* [*Free Regsitration Required]|
This is a preview of subscription content, log in to check access. Cancer Treat Rep — Google Scholar. Lippincott, Philadelphia, pp 71—83 Google Scholar. De Mulder P, Sternberg CN: A randomized phase II trial with 5-fluorouracil, cisplatin and interferon alpha in second line in advanced transitional cell cancer of the urothelial tract. Urology 15—20 CrossRef Google Scholar.
Fair WR Controversies in the management of transitional cell carcinoma of the bladder. Fair WR Organ conservation in deeply invasive bladder tumors: a valid approach? Lippincott, Philadelphia, pp — Google Scholar. Gospodarowicz MK, Warde P The role of radiation therapy in the management of transitional cell carcinoma of the bladder.
The T1 bladder tumor. J Clin Oncol 6: — Google Scholar. Cancer — CrossRef Google Scholar. J Clin Oncol 3: — Google Scholar. Onkologie — CrossRef Google Scholar.
Loehrer PJ Chemoradiotherapy in locally advanced bladder carcinoma. A prospective intergroup trial comparing single agent cisplatin CDDP vs. Anderson experience. J Urol 33—37 Google Scholar. National Cancer Institute. Porter AT Radiotherapy combined with chemotherapy in treatment of muscle-invasive bladder carcinoma.
Roth BJ Preliminary experience with paclitaxel in advanced bladder cancer. Scher HI Chemotherapy for invasive bladder cancer: neoadjuvant versus adjuvant. Scher HI New approaches to the treatment of bladder cancer.
Progress in clinical and biological research Sternberg CN Organ conservation in T2—3 bladder cancer: the role of transurethral resection, partial cystectomy, and primary and adjuvant chemotherapy. World J Urol 2—7 Google Scholar.
Sternberg CN Post cystectomy adjuvant chemotherapy: a clinical routine? Sternberg CN The treatment of advanced bladder cancer. Ann Oncol 6: Google Scholar. Ann Oncol 4: — Google Scholar. Results of a controlled prospective study.
J Urol — Google Scholar. J Urol Google Scholar. Results of a prospective randomized trial. J Urol 81—84 Google Scholar. Thrasher JB, Crawford ED Current management of invasive and metastatic transitional cell carcinoma of the bladder. Department of Health and Human Services Cancer rates and risks.
Yagoda A, Olsson C Neoplasms of the kidney, bladder and prostate. Basic Principles and clinical management of cancer. In: Perry MC ed The chemotherapy source book. Zietman A, Shipley WU, Kaufman DS The combination of cis-platin based chemotherapy and radiation in the management of muscle-invading transitional cell cancer of the bladder.
Schmoll There are no affiliations available. Personalised recommendations. Cite chapter How to cite? ENW EndNote. Buy options.
The three focus areas catch emerging trends of our time: Innovation and change management are becoming increasingly important in a society in rapid technological and social evolution. Reputation, social responsibility and ethics are receiving increased attention in a more and more transparent and communicative world. And , last but not least, this increases the demands on leadership skills and managerial development. At a time when both industry and society expect the board to take an active role in the formulation of corporate strategy, it is also important that the board has expertise in these areas. The course combines theory and practice: It gives participants insight into the main contribution to the fundamental thinking in the three focus areas, and combines it with 'hands on' experience from practical cases. This includes, understand the chairman's special role and tasks as well as the challenges facing external directors. This includes understanding the governance hurdles in phases of corporate development from entrepreneur phase until mature product; and governance challenges of intrapreneurship and restructuring in mature companies.
BIK 2943 Board Development, Innovation Management and Social Responsiblity